When will NexVas™ PR small molecules be available to patients?
Like other experimental drugs, NexVas™ PR will not be available to the public until its safety and efficacy has been tested in rigorous clinical trials and approved for use by regulatory bodies such as Health Canada and the U.S. Food & Drug Administration (FDA). Resverlogix will begin its first administration in man studies in the first quarter of 2007, with a potential Phase I trial expected to follow later in the same year.
